Skip to main content
OpenTrials

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,144 public trials 77 recruiting studies
Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

Ph IIA Study (SOC +/- NS5B)

NCT01193361

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Advanced Clinical Research Institute Anaheim, California, United States
  • Loyola University Medical Center Maywood, Illinois, United States
  • Mercy Medical Center Baltimore, Maryland, United States
  • Digestive Disease Associates, P.A. Baltimore, Maryland, United States
View Trial Details
Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

NCT00664625

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations
  • Advanced Clinical Res Inst Anaheim, California, United States
  • West Coast Clinical Trials, Llc Cypress, California, United States
  • Washington University School Of Medicine St Louis, Missouri, United States
  • University Of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

NCT01573351

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Scripps Clinic La Jolla, California, United States
  • Scpmg/ Kaiser Permanente Los Angeles Medical Center Los Angeles, California, United States
  • University Of Colorado Denver And Hospital Aurora, Colorado, United States
View all 79 locations
View Trial Details
Completed

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

NCT01718145

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Nagoya, Aichi-ken, Japan
  • Local Institution Toyoake Shi, Aichi-ken, Japan
  • Local Institution Chiba, Japan
  • Local Institution Fukui-shi, Fukui, Japan
View all 48 locations
View Trial Details
Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • Desert Medical Group Inc. Palm Springs, California, United States
  • University Of Colorado Denver And Hospital Aurora, Colorado, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
View all 40 locations
View Trial Details
Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

NCT01581203

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • The Health Care Authority For Baptist Health Montgomery, Alabama, United States
  • Scripps Clinic La Jolla, California, United States
  • Scpmg/ Kaiser Permanente Los Angeles Medical Center Los Angeles, California, United States
  • University Of Colorado Denver And Hospital Aurora, Colorado, United States
View all 116 locations
View Trial Details
Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • University Of Alabama At Birmingham Birmingham, Alabama, United States
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Florida Hospital Transplant Center Orlando, Florida, United States
  • Mercy Medical Center Baltimore, Maryland, United States
View all 40 locations
View Trial Details

Related conditions